December 3, 2021

Announcements

Dr. John Lewin Named Chief of Breast Imaging
On behalf of the Department of Radiology & Biomedical Imaging, we are delighted to announce that John M. Lewin, MD, FACR, will join Yale Cancer Center, Smilow Cancer Hospital, and Yale School of Medicine’s Department of Radiology & Biomedical Imaging as Breast Imaging Division Chief.

Dr. Lewin completed his undergraduate and medical education at Harvard University followed by residency and breast imaging fellowship at the University of Colorado Health Sciences Center. He remained in Colorado, working successfully in both academic and private practice settings. He has served on many national radiology committees including the American College of Radiology Imaging Network (ACRIN) Working Group on Digital Mammography, the American College of Radiology (ACR) Breast MRI Lexicon Working Group, and the ACR Contrast Mammography BI-RADS Group. He is currently the Vice President for the Society of Breast Imaging (SBI) and will serve as SBI President in 2022.

Dr. Lewin has funded research related to image processing/advancing technical innovations in breast imaging, including contrast-enhanced mammography and cancer laser ablation techniques. He has also won several research awards during his career.

Dr. David Braun Joins CMCO
David Braun, MD, PhD, has been appointed an Assistant Professor of Medicine (Medical Oncology) and joins the Center of Molecular and Cellular Oncology (CMCO) at Yale Cancer Center. Dr.
Yale Cancer Center. Dr. Braun cares for patients with kidney cancers. He received his PhD in Computational Biology from the Courant Institute of Mathematical Science at New York University and his medical degree from Icahn School of Medicine at Mount Sinai. He completed his residency at the Brigham and Women’s Hospital where he received the Dunn Medical Intern Award and served as Chief Medical Resident before completing fellowship training in adult oncology through the Dana-Farber/Partners CancerCare program where he was appointed the Emil Frei Fellow and the John R. Svenson Fellow.

Dr. Braun joins Yale from Dana-Farber Cancer Institute where he was an Instructor in Medicine with clinical and scientific interest in understanding and improving immune therapies for kidney cancer. He has a longstanding interest in integrating experimental and computational approaches to biomedical research and is currently studying mechanisms of response and resistance to immune therapy in kidney cancer, with the goal of developing novel therapies. He will continue this work as part of the CMCO, which fosters and mentors physician-scientists as they advance their laboratory-based research programs to bridge fundamental cancer biology with clinical investigation for the translation of basic discoveries into better treatments or diagnosis.

Yale Cancer Center Research at National Meetings
Our Hematology and Breast Cancer teams will close out a busy year with participation in annual meetings in December. Beginning December 8, our Hematology Program will participate in the 63rd American Society of Hematology (ASH) Annual Meeting with presentations on clinical and research advances for the treatment of hematologic malignancies. In addition, our Breast Cancer team will participate in the annual San Antonio Breast Cancer Symposium (SABCS) starting on December 7. Please review the presentations from Yale scheduled to be presented at ASH and SABCS and support your colleagues during their hybrid presentations.

Notables

Stacey Stein, MD, Associate Professor of Medicine (Medical Oncology), has been selected to participate in the Yale New Haven Health Institute of Excellence 2021-22 Lean in Circle. The program provides women leaders with the opportunity to speak openly about the challenges faced in the workforce, foster mentorship, engage in shared problem solving and empower the pursuit of professional achievements.

Eric Song, a sixth-year MD/PhD student in the laboratory of Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Professor of Immunobiology, Professor of Molecular, Cellular and Developmental Biology and of Epidemiology (Microbial Diseases), and a member of Yale Cancer Center’s Cancer Immunology Program, has been selected to participate in the 63rd annual meeting of the American Association for the Advancement of Science (AAAS). He will present research on the role of the innate immune system in the development of breast cancer.

Pathologist Robert Homer, MD, PhD, on Lung Cancer Awareness Month

"I actively participate in the Yale SPORE in Lung Cancer as the diagnostic pathologist on the team. Our current focus is on advancing targeted treatment options for lung cancer to benefit our patients using immunotherapy and molecular treatments."

Read More

Early Detection Research at Yale Cancer Center Could be a Game Changer for Hard to Diagnose Pancreatic Cancer

Read More
Eric has been actively engaged in research since his junior year in college, with 23 publications before he started his graduate program at Yale. He now has spent nearly a decade developing with therapies for brain tumors and has co-authored close to 60-peer reviewed articles.

Prasanna Ananth, MD, MPH, Assistant Professor of Pediatrics (Hematology/Oncology) and a member of Yale Cancer Center’s Cancer Prevention and Control Research Program, has been elected to membership in the Society for Pediatric Research.

Sajid A. Khan, MD, Associate Professor of Surgery (Surgical Oncology) and a member of Yale Cancer Center’s Genetics, Genomics, and Epigenetics Research Program, has been appointed to the editorial board in the Translational Research Section of the Annals of Surgical Oncology.

Aaron Ring, MD, PhD, Assistant Professor of Immunobiology and a member of Yale Cancer Center’s Cancer Immunology Research Program, has been named to Nature Biotechnology’s list of "Top 20 Translational Researchers of 2020," which recognizes success in patenting.

Patricia LoRusso, DO, Professor of Medicine (Medical Oncology) and Associate Cancer Center Director for Experimental Therapeutics, has been named Chair of the American Association for Cancer Research (AACR) KRAS Task Force to lead the AACR KRAS Symposium in 2022.

Valentina Greco, PhD, Carolyn Walch Slayman Professor of Genetics and a member of Yale Cancer Center’s Cancer Signaling Networks Research Program, is president-elect of the Society for Investigative Dermatology for 2021-22. Dr. Greco takes office as president next year.

Caro Kravitz, a fourth-year graduate student in the laboratory of Don Nguyen, PhD, has been awarded a F31 grant to support her project, “Determining the Molecular Contributions of KDM2A in NSCLC Metastasis.” Caro is studying the mechanism by which a specific epigenetic modifier, KDM2A, contributes to the metastatic capacity of KRAS mutant Non-Small Cell Lung Cancer.

Matt Murray, a fourth-year PhD candidate in the laboratory of Ranjit Bindra, MD, PhD, has been awarded a F31 Diversity Grant to support a collaborative project with the laboratory of W. Mark Saltzman, PhD, to study gliomas. Specifically, he is looking to develop and utilize nanoparticle-encapsulated inhibitors for the treatment of diffuse intrinsic pontine glioma (DIPG) with high efficacy and low toxicity.

The Institute for Scientific Information has named 26 Yale School of Medicine faculty members, including 15 members from Yale Cancer Center, among 2021’s most influential scientists based on citations to their publications from 2010 to 2020. The Institute recognizes true pioneers in their fields, demonstrated by the production of multiple highly cited papers that rank in the top 1% by citations for field and year in the Web of Science™. Of the world’s scientists and social scientists, Highly Cited Researchers are one in 1,000. Yale Cancer Center members recognized include:
Craig Crews, PhD, John C. Malone Professor of Molecular, Cellular, and Developmental Biology and Professor of Chemistry, of Pharmacology, and of Management; Executive Director, Yale Center for Molecular Discovery

Lieping Chen, MD, PhD, United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology); Co-Leader, Cancer Immunology Research Program, Yale Cancer Center

Mark Gerstein, PhD, Albert L Williams Professor of Biomedical Informatics and Professor of Molecular Biophysics & Biochemistry, of Computer Science, and of Statistics & Data Science

Scott Gettinger, MD, Professor of Internal Medicine (Medical Oncology); Chief, Thoracic Medical Oncology

Andrew Goodman, PhD, C.N.H. Long Professor of Microbial Pathogenesis and Director of Microbial Sciences Institute

David A. Hafler, MD, FANA, William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology; Chair, Department of Neurology; Neurologist-in-Chief, Yale New Haven Hospital

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science

Silvio Inzucchi, MD, Professor of Medicine (Endocrinology)

Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Professor of Immunobiology; Professor of Molecular, Cellular and Developmental Biology; Professor of Epidemiology (Microbial Diseases); Professor of Molecular Cellular and Developmental Biology; Investigator, Howard Hughes Medical Institute

Grace Kong, PhD, Assistant Professor of Psychiatry

Suchitra Krishnan-Sarin, PhD, Professor of Psychiatry; Chair, Human Investigations Committee (IRB), Human Research Protections Program

Ruslan Medzhitov, PhD, Sterling Professor of Immunobiology; Investigator, Howard Hughes Medical Institute

David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and Professor of Medicine (Medical Oncology); Director, Yale Cancer Center Tissue Microarray Facility, Pathology; Director, Yale Pathology Tissue Services, Pathology; Director, Physician Scientist Training Program, Pathology Research

Gerald Shulman, MD, PhD, George R. Cowgill Professor of Medicine (Endocrinology) and Professor of Cellular and Molecular Physiology; Co-Director, Yale Diabetes Research Center, Internal Medicine

Mario Sznol, MD, Professor of Medicine (Medical Oncology); Co-Leader, Cancer Immunology Research Program, Yale Cancer Center; Co-Director, Yale SPORE in Skin Cancer

The Cancer Signaling Network Research Program welcomes Won Jae Huh, MD, PhD, Assistant Professor of Pathology. Dr. Huh is a physician-scientist with clinical expertise in Gastrointestinal Pathology. His laboratory work is focused on signaling mechanisms involved including EGFR and NOTCH.

Riley Norwood (l) and Alyssa Milburn (r) teamed up with their school Mount Saint Mary College in Newburgh, NY, the Student
including EGFR and NOTCH signaling in gastric premalignant disease. Dr. Huh’s contribution in the field of gastric physiology and pathophysiology includes elucidating the role of transcription factor XBP1 in the differentiation of the gastric chief cell lineage, the development of a spasmolytic polypeptide-expressing metaplasia (SPEM) mouse model, demonstration of the genotoxicity of tamoxifen-inducible Cre recombinase, CreERT2, characterization of novel EGFR reporter mouse line, EgfrEmeraldGFP (Em), and first available neutralizing antibodies, P1X and P2X, to mouse EGFR.

Diversity, Equity, and Inclusion

The National Institutes of Health (NIH) launched the UNITE initiative in March of 2021 to address structural racism in the biomedical research enterprise. Through this initiative, the NIH is holding a series of listening sessions and welcomes your attendance to share full range of issues and challenges in advancing racial and ethnic equity in the biomedical research enterprise. Some of these issues include:

- Changing culture to promote equity, inclusivity, and justice
- Improving policies, transparency, and oversight
- Strengthening career pathways, training, mentoring, and the professoriate
- Ensuring fairness in review and funding deliberations
- Enhancing funding and research support for diverse institutions and historically under-resourced research areas
- Structural racism in the biomedical research enterprise

The insights shared during these listening sessions will help to identify priorities for UNITE and inform the development of an NIH action plan. If interested, please register to join an upcoming session.

Employee Profile: Sylvia Lempit

Sylvia Lempit, APRN with the Smilow Liver Cancer Program, is a rare gem according to Dr. Mario Strazzabosco, Professor of Medicine and Clinical Program Leader of the Liver Cancer Program. "She specializes in liver disease, liver cancer, and liver transplant, which is a unique combination that you don’t find everywhere."

When Sylvia joined Yale in 2006, it was a second career for her. After working in human resources at Mary College in Newburgh, NY, the Student Nurses Association and the Student Government to raise support for the Smilow Breast Cancer Program through fundraising and raffles at their Pink Out soccer games. This effort is greatly appreciated and we applaud these wonderful ladies!

Do you currently smoke cigarettes? You may be eligible for a paid Yale University study investigating alternative nicotine products. Click the link below or call/text 203-464-7850 for more information. All calls are confidential.

It’s #GivingTuesday! All donations made to Closer to Free support Smilow Cancer Hospital and Yale Cancer Center’s mission to pursue the latest advances in cancer research at Yale Cancer Center, develop promising new cancer treatments, and make your contributions count!
for her. After working in human resources and taking time off to raise her family, she decided to become an EMT and go back to school full-time. She graduated from Yale School of Nursing and then completed a year-long fellowship funded by the American Association for the Study of Liver Disease (AASLD) Foundation. In her current role with the Liver Cancer Program, which she joined in 2016, Sylvia sees patients in New Haven and at a pre-care clinic in Bridgeport where she cares for underserved patients with liver abnormalities. A very important component of her work is getting patients treatment for Hepatitis C virus and access into the health care system. She also provides counseling and meets with patients to assess their liver function and help plan next steps. Although she does not administer therapies, she works closely with Medical Oncology, Interventional Oncology, and Surgical Oncology while patients are undergoing treatment to help maintain liver function.

Sylvia follows patients from the time of diagnosis until it is time to transition to palliative or hospice care. "Patients with liver disease run the gamut, and I have pretty much seen it all," said Sylvia. "Once therapy to treat their cancer is no longer recommended, I continue to monitor liver function and provide interventions and resources to keep them as stable as possible for as long as possible. Patients and their families are so appreciative of this extra support we provide."

Sylvia has patients that were diagnosed years ago, and she still follows them very closely; in fact, the follow-up and surveillance is so rigorous that often other cancers and diseases are found. As this patient population is at high-risk for complications from COVID-19 infection, a lot of her time is also spent educating them on the importance of getting the COVID-19 vaccine.

Recent Publications


21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer


Read More

Gilani SM, Abi-Raad R, Garritano J, Cai G, Prasad ML, Adeniran AJ.

*RAS Mutation and Associated Risk of Malignancy In The Thyroid Gland: An FNA Study With Cytology-Histology Correlation*

*Cancer Cytopathology,* Online ahead of print.

Read More

Lung Screenings Save Lives

Lung cancer is by far the leading cause of cancer related deaths. Lung screening with CT scans can save lives by identifying lung cancer early.
Hepatology Communications, Online ahead of print.
Read More

Supportive Care in Cancer, Online ahead of print.
Read More

Lee V, An Y, Park HS, Yu JB, Kim SP, Jairam V. Emergency Department Visits for Radiation Cystitis Among Patients with a Prostate Cancer History
BJU International, Online ahead of print.
Read More

European Journal of Cancer, Online ahead of print.
Read More

European Respiratory Journal, Online ahead of print.
Read More

Seminars in Liver Disease, Online ahead of print.
Read More

Burtness, B. A commentary on: Hypoxia-Guided Therapy for Head and Neck Cancers Practice Update Website.
Read More

European Journal of Cancer, Online ahead of print.
Read More

Read More

Follow Yale Cancer Center on Twitter

“Recommended screening significantly reduces cancer-related deaths; the numbers are astounding.”
— Dr. Xavier Llor, @NCCN panel Vice-Chair on new patient screening guidelines for colorectal cancer.

New practice changing #breastcancer data from the RxPonder study with Dr. Lajos Pustzai & colleagues nationwide shows chemoendocrine therapy had longer disease–free survival in premenopausal women v. endocrine-only therapy.

Tune in as @AnneChiangMD provides expert analysis and summaries of key studies presented at #WCLC21.

Join us at 12pm today for grand rounds presented by Dr. Omar Abdel-Wahab @AbdelWahablab @sloan_kettering who will give the Blanche Tullman Lectureship in #Hematology on "Novel Targeted Therapeutics for #Leukemia."

“Maybe a 70-year-old of the future will look more like a 40 or 50-year-old of today.” — Dr. Morgan Levine discussed
Evorpacept Alone And In Combination With Pembrolizumab Or Trastuzumab In Patients With Advanced Solid Tumours (ASPEN-01): A First-In-Human, Open-Label, Multicentre, Phase 1 Dose-Escalation And Dose-Expansion Study
*Lancet Oncology*, Online ahead of print.

Read More


177 Lu-Dotatate Plus Long-Acting Octreotide Versus High-Dose Long-Acting Octreotide In Patients With Midgut Neuroendocrine Tumours (NETTER-1): Final Overall Survival And Long-Term Safety Results From An Open-Label, Randomised, Controlled, Phase 3 Trial
*Lancet Oncology*, Online ahead of print.

Read More

Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D.

Incidence, Risk Factors, And Mortality Of Atrial Fibrillation In Breast Cancer: A SEER-Medicare Analysis
*European Heart Journal*, Online ahead of print.

Read More

Clark M, Kollara A, Brown TJ, May T.

A Mouse Model Of Neoadjuvant Chemotherapy Followed By Interval Cytoreductive Surgery Indicates Impaired Efficacy Of Perioperative Cisplatin

Read More


Premetastatic Shifts Of Endogenous And Exogenous Mutational Processes Supports Consolidative Therapy In EGFR-Driven Lung Adenocarcinoma
*Cancer Letters*, Online ahead of print.

Read More


Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs)
*ACS Chemical Biology*, Online ahead of print.

Read More

Wagner GP, Kshizit, Dighe A, Levchenko A.

The Coevolution of Placentation and Cancer

Read More

Torres AR, Johnson NP, Ellingson MK, Hansen CE, Oliveira CR, Niccolai LM, Sheth SS.


Calendar

**Yale Cancer Answers**
December 5; 7:30 PM
NPR
*Advances in Colon and Rectal Surgery*
Ira Leeds, MD, MBA, ScM
Learn More

**Radiobiology and Genome Integrity Research Program**
December 6; 11:00 AM
*Are Cancers Addicted to Aneuploidy?*
Jason Sheltzer, PhD
Learn More

**Cognitive Behavioral Therapy: Skills Group for Cancer Survivors**
December 6, 2:30 PM
Learn More

**Yale Cancer Center Grand Rounds**
December 7; 12:00 PM
*Management of Spinal Tumors and New Directions in Lung Stereotactic Body Radiotherapy*
Ehud Mendel, MD, MBA and Henry S. Park, MD, MPH
Learn More

**Yale Center for Immuno-Oncology Seminar**
(presented as part of the Human and Translational Immunology Program Seminar Series)
December 7, 4:00 PM
*Cell Therapies for Cancer – Beyond CARs*
Catherine Bollard, MD, MBChB
Learn More

**Pathology Grand Rounds**
December 9; 12:30 PM
*Race in Medicine: Data or Distraction?*
Andres Dreyer, MD, PhD and Joseph L.
Learn More

#WorldPancreaticCancerDay is today! Dr. @JamesFarrellGI shares his thoughts on the future of ancreaticcancer and his research into early detection and prevention.

Thank you to our Center for thoracic Cancers @SmilowCancer team for a fantastic Smilow Shares presentation in honor of #LungCancerAwarenessMonth
Omuro, A.

**Editorial: Advances In Neuro-Oncology: Stepping In The Right Direction**

*Current Opinion in Neurology, 34*(6):825-826.

**Read More**

Pak LM, Purad CC, Nadipally S, Rao MP, Mukherjee S, Hegde SKB, Golshan M.

**ASO Visual Abstract: Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program**


**Read More**

Bewersdorf JP, Patel KK, Huntington SF, Zeidan AM.

**Cost-effectiveness Analysis Of Oral Azacitidine Maintenance Therapy In Acute Myeloid Leukemia**


**Read More**

Shammas RL, Fish LJ, Sergesketter AR, Offodile AC 2nd, Phillips BT, Oshima S, Lee CN, Hollenbeck ST, Greenup RA.


*Annals of Surgical Oncology, 28*(Suppl 3):720-721

**Read More**

---

**Funding and Award Opportunities**

**HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required)**

The purpose of this FOA is to solicit applications to accelerate development, testing and implementation of evidence-based interventions—that are culturally and linguistically appropriate for NIH-designated populations that experience health disparities in the United States—to mitigate disparities in provision of care and treatment decisions, reduce susceptibility to chronic pain and improve patient outcomes.

**Application Deadline:** December 9, 2021

**Read More**

**ASCO Women Who Conquer Cancer Mentorship Awards**

The awards recognize extraordinary women leaders in oncology and role models who have excelled as a mentor and have demonstrated outstanding commitment to the professional development of women colleagues as clinicians, educators, and researchers in oncology.

**Application Deadline:** December 10, 2021

**Read More**

**The Conquer Cancer – Breast Cancer Research Foundation Research Professorship for Diversity and Inclusion in Breast Cancer**

Provides flexible funding to outstanding researchers who have made, and are continuing to make, significant contributions in breast cancer research and will dedicate their time in training future breast cancer researchers.

**Letter of Intent Due:** December 14, 2021

**Read More**

---
The Conquer Cancer – Breast Cancer Research Foundation Advanced Clinical Research Award (ACRA) for Diversity and Inclusion in Breast Cancer Research

Designed with the primary goal of increasing diversity in the oncology workforce and cancer research. Awards will be given to mid-career investigators who are members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research, and who wish to conduct original breast cancer research not currently funded.

Letter of Intent Due: December 14, 2021

HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3)

The purpose of this FOA is to solicit cooperative agreement applications to conduct multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. Trials may include or allow continuation of opioid medication as needed; however opioid medication use alone should not be the only intervention studied. Trials supported under this initiative could also address social and structural barriers such as stigma and racial bias to SCD pain management care.

Application Deadline: December 15, 2021


The purpose of this FOA is to solicit cooperative agreement applications to support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed.

Application Deadline: December 15, 2021

Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01)

The purpose of this FOA is to support and accelerate the integration of evidence-based cancer control interventions for PLWH by leveraging existing HIV treatment and prevention infrastructure.

Application Deadline: December 15, 2021

Alex’s Lemonade Stand Foundation (ALSF) and RUNX1 Early Career Investigator Grant

The purpose of this grant is to promote the establishment of a new generation of translational and clinical researchers interested in tackling inherited hematologic malignancy predisposition disorders with a focus on RUNX1-familial platelet disorder.

Application Deadline: December 20, 2021
Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24)

Through this FOA, the NCI solicits applications from institutions/organizations to participate in the Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network. The ‘CASCADE’ Network will conduct pragmatic clinical trials evaluating the effectiveness of clinically proven interventions to overcome barriers and reduce failures in the cervical cancer screening, management, and precancer treatment cascade for women living with HIV.

**Application Deadline:** December 28, 2021

Read More

Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1)

As an integral part of this Cooperative Agreement-funded network, this FOA will (i) provide scientific and statistical leadership for developing network clinical trials concepts and protocols, overseeing their conduct, and analyzing and publishing their results, (ii) ensure compliance with human research participant protection and other regulatory and administrative reporting requirements, and (iii) work towards creating opportunities for training emerging investigators.

**Application Deadline:** December 28, 2021

Read More

Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1)

As an integral part of this Cooperative Agreement-funded network, this FOA will provide a pluripotent infrastructure for accruing participants to network clinical trials, interface with the UG1 Research Bases and U24 Network Coordinating Center during concept and protocol development to provide insights and input on clinical significance and study feasibility and provide on-site operational leadership for the successful conduct of the network clinical trials.

**Application Deadline:** December 28, 2021

Read More

Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program Scholar Awards

We are pleased to solicit applications for the Yale Cancer Center (YCC) K12 Calabresi Immuno-Oncology Training Program (IOTP) Scholar Award for junior faculty to enhance research skills beyond the training provided during graduate and postgraduate training.

**Application Deadline:** January 3, 2022

Read More

YCC Cancer Microbiome Pilot Grants

Thanks to the generosity of a private donor, YCC seeks to fund early-stage laboratory investigations that will advance our understanding of the host microbiome and microbial niches in cancer progression and therapy. Cancer associated microorganisms include bacteria, viruses, fungi, and parasites.

**Application Deadline:** January 3, 2021

Read More

Mary Kay Ash Foundation Cancer Research Grant

The Mary Kay Ash Foundation awards grants to support researchers at any academic stage who are committed to enhancing the study of cancer, including translational research.

**Application Deadline:** January 3, 2021

Read More

Submissions

Please submit your recent publications, awards, and grant announcements to:

**Renee Gaudette**
Director, Public Affairs and Communications
This grant focuses on funding research for innovative grants for translational research of cancers affecting women (ovarian, uterine, breast, endometrial or cervical cancer among others).

**Internal Deadline:** January 3, 2021

**Read More**

**Brain Research Foundation: Brain Research Foundation Seed Grant Program 2022**
The objective of the BRF Seed Grant Program is to support new and innovative projects, especially those of junior faculty, who are working in new research directions. BRF Seed Grant awards are not intended to supplement existing grants.

**Application Deadline:** January 4, 2021

**Read More**

**AACR Cancer Disparities Research Fellowships**
These represent an effort to encourage and support postdoctoral or clinical research fellows to conduct cancer disparities research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to cancer disparities.

**Application Deadline:** January 7, 2022

**Read More**

**CDA for Inclusion and Diversity in Breast Cancer Research**
Designed with the primary goal of increasing diversity in the oncology workforce and cancer research. This CDA will provide funding to clinical investigators who have received their initial faculty appointment and identify as members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research.

**Application Deadline:** January 10, 2022

**Read More**

**YIA for Diversity and Inclusion in Breast Cancer Research**
Provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this grant is to fund physicians during the transition from a fellowship program to a faculty appointment.

**Application Deadline:** January 10, 2022

**Read More**

**HESI THRIVE**
THRIVE, a partner in the 2018 Biden Cancer Initiative, provides seed grants for nonclinical, clinical, and translational research and technology-based solutions that enhance our ability to predict when and how adverse effects may occur in patients who have received cancer treatment. THRIVE also supports the development of approaches to avoid or lessen these effects.

**Letter of Intent Due:** January 10, 2022

**Read More**

**Bladder Cancer Research Innovation Awards**
This award supports experienced investigators with exceptionally novel and creative projects designed to produce significant advances in our understanding of the management of bladder cancer. The proposed research may be basic, translational, clinical or epidemiological and must have direct applicability and relevance to bladder cancer. Applications must include innovative approaches and new ideas to be eligible for funding.
innovative approaches and new ideas to be eligible for funding.

**Application Deadline:** January 12, 2022

Read More

**Susan D. Flynn Oncology Nursing Fellowship at Smilow Cancer Hospital**

The Susan D. Flynn Oncology Nursing Fellowship Program at Smilow Cancer Hospital is intended to help stimulate the career interest and foster the professional development of future oncology nurses. Since 2014, Greenwich Hospital has been home to the Fellowship, but this year the program will be expanded to Smilow Cancer Hospital in New Haven as well. Six undergraduate nursing students enrolled in a BSN program who have just completed their junior year will be chosen for an immersive 8-week experience in oncology nursing; two at Greenwich Hospital and four in New Haven.

The fellowship will enhance the student’s core clinical education through direct observation and exposure to oncology nursing care. Through this experience, students will learn about the various oncology nursing roles and responsibilities and discover possible career opportunities.

**Application Deadline:** January 14, 2022. Applications should be sent to: kristina.capretti@greenwichhospital.org

http://sdfondp.com/

**The Jackson Laboratory – Yale Cancer Center Joint Pilot Project Grant: Deciphering the Tumor Microenvironment Using Advanced Imaging and Analysis**

The pilot funding will support innovative cancer research on the topic of “Deciphering the Tumor Microenvironment Using Advanced Imaging and Analysis.” Proposals may be focused on spatial data analysis, technology investigation, or hypothesis-based research making innovative use of advanced imaging techniques.

**Proposals are due by:** January 14, 2022. Email your application to jaxccadmin@jax.org

Read More

**BMSF Diversity in Clinical Trials Career Development Program**

The intent of this program is to increase diversity in clinical trials. The initiative is comprised of a Career Development Program for early-stage clinical investigators and a Clinical Investigator Pipeline Program (BMSF CIPP) for rising second-year medical students.

**Application Deadline:** January 14, 2022

Read More

**ASCO Medical Student Rotation for Underrepresented Populations**

Provides financial support for U.S. medical students from populations underrepresented in medicine and who are interested in oncology as a career to experience a minimum 4-week clinical or clinical research rotation.

**Application Deadline:** January 25, 2022

Read More

**ASCO Diversity Mentoring Program**

Designed to encourage U.S. based medical students and residents who are underrepresented in medicine to pursue rewarding careers in oncology by pairing with a mentor.
BMSF Clinical Investigator Pipeline Program
This Program was established to build the pipeline of community oriented clinical trialists of diverse backgrounds who are committed to increasing diversity, equity and inclusion in clinical trials. This will be a 6-week summer externship program for 250 underrepresented medical students, and with hands-on community-oriented clinical trial experience in underserved communities.

Application Deadline: January 28th, 2022
Read More

Leslie Warner Postdoctoral Fellowships for Cancer Research
The Fellowships will support early-stage promising trainees that are conducting innovative basic, translational, clinical, or population-based cancer research with a Yale Cancer Center member. Relevance of proposed research to our catchment area priorities is also encouraged. Candidates may have up to one year of postdoctoral experience from the time of application.

Internal Deadline: February 1, 2022
Read More

Leukemia Research Foundation Grant
The application process for the 2022-2023 funding cycle has begun! Grants of up to $100K are available to new investigators -- researchers within seven years of their first independent faculty-level position. Research projects must focus on a blood cancer (leukemia, lymphoma, myeloma, or MDS).

Letter of Intent Due: February 4, 2022
Read More

Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01, R21)
The purpose of this FOA is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies.

Application Deadline: February 5, 2022
Read More

Early K99/R00 Funding Opportunity Announcements
The NCI just reissued “early K99/R00” - NCI Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers FOAs that might be of interest to some postdoctoral fellows.

♦ NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
♦ NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
♦ NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

Application Deadlines: February 28, 2022
Read More
NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)
The purpose of this award is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions.

**Application Deadline:** February 28, 2022

Read More

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)
This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

**Application Deadline:** February 28, 2022

Read More

DeLuca Career Development Award 2022
The purpose of this career development award is to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes and with the ultimate goal to achieve independent support for their research from a national agency. For further information contact Richard.Carr@yale.edu

**Letter of Intent Due:** March 1, 2022

Read More